X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
index medicus (9) 9
alectinib (8) 8
male (8) 8
crizotinib (7) 7
female (7) 7
middle aged (7) 7
adult (6) 6
carcinoma, non-small-cell lung - drug therapy (6) 6
lung neoplasms - drug therapy (6) 6
oncology (6) 6
carbazoles - therapeutic use (5) 5
pharmacology & pharmacy (5) 5
piperidines - therapeutic use (5) 5
analysis (4) 4
antitumor-activity (4) 4
carbazoles - adverse effects (4) 4
lung cancer (4) 4
lung cancer, non-small cell (4) 4
nsclc (4) 4
piperidines - adverse effects (4) 4
receptor protein-tyrosine kinases - antagonists & inhibitors (4) 4
treatment outcome (4) 4
aged (3) 3
cancer therapies (3) 3
carbazoles - administration & dosage (3) 3
carcinoma, non-small-cell lung - enzymology (3) 3
cell lung-cancer (3) 3
central nervous system (3) 3
chemotherapy (3) 3
drug resistance, neoplasm (3) 3
drugs (3) 3
lung neoplasms - enzymology (3) 3
lymphoma (3) 3
models (3) 3
non-small cell lung carcinoma (3) 3
patients (3) 3
pharmacokinetics (3) 3
piperidines - administration & dosage (3) 3
protein kinase inhibitors - administration & dosage (3) 3
protein-tyrosine kinase (3) 3
pyrazoles - therapeutic use (3) 3
pyridines - therapeutic use (3) 3
risk factors (3) 3
safety (3) 3
alk inhibitor (2) 2
anaplastic lymphoma kinase (2) 2
animals (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
cancer (2) 2
cancer research (2) 2
carbazoles - pharmacokinetics (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
central nervous system neoplasms - secondary (2) 2
ceritinib (2) 2
confidence intervals (2) 2
diabetes mellitus, type 2 - drug therapy (2) 2
disease (2) 2
disease-free survival (2) 2
dose-response relationship, drug (2) 2
drug dosages (2) 2
exposure (2) 2
follow-up studies (2) 2
healthy-subjects (2) 2
hypoglycemic agents - therapeutic use (2) 2
inhibitor alectinib (2) 2
kaplan-meier estimate (2) 2
lung neoplasms - pathology (2) 2
medicine & public health (2) 2
metastasis (2) 2
mutation (2) 2
non-small cell lung cancer (2) 2
non–small cell lung cancer (2) 2
open-label (2) 2
pharmacology (2) 2
pharmacology/toxicology (2) 2
piperidines - pharmacokinetics (2) 2
pooled analysis (2) 2
protein kinase inhibitors - adverse effects (2) 2
protein kinase inhibitors - therapeutic use (2) 2
receptor protein-tyrosine kinases - analysis (2) 2
respiratory system (2) 2
therapy (2) 2
tumors (2) 2
young adult (2) 2
abridged index medicus (1) 1
absorption (1) 1
achilles-heel (1) 1
activated-receptor-gamma (1) 1
administration, oral (1) 1
adrenergic beta-antagonists - therapeutic use (1) 1
adverse cardiovascular events (1) 1
aged, 80 and over (1) 1
alanine (1) 1
alanine transaminase (1) 1
alanine transaminase - blood (1) 1
alex (1) 1
algorithms (1) 1
alk (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 08/2019, Volume 20, Issue 17, p. 4230
In the current study we investigate the mechanisms of action of short acting inhaled insulin Exubera®, on hepatic glucose production (HGP), plasma glucose and... 
disposition index | hepatic glucose production | OGTT | inhaled insulin | whole body glucose metabolism | tracers
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 7, pp. 661 - 668
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2018, Volume 82, Issue 1, pp. 129 - 138
Alectinib is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor that is active in the central nervous system (CNS). Alectinib demonstrated... 
Alectinib | Medicine & Public Health | ALK inhibitor | NSCLC | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | Exposure response | HEALTHY-SUBJECTS | INHIBITOR ALECTINIB | ANTITUMOR-ACTIVITY | ER | MODELS | DRUGS | BRAIN METASTASES | PHARMACOLOGY & PHARMACY | MUTATIONS | Lung Neoplasms - drug therapy | Humans | Middle Aged | Carbazoles - administration & dosage | Drug Resistance, Neoplasm | Male | Protein Kinase Inhibitors - adverse effects | Anaplastic Lymphoma Kinase - genetics | Dose-Response Relationship, Drug | Multicenter Studies as Topic | Female | Lung Neoplasms - genetics | Carbazoles - adverse effects | Piperidines - administration & dosage | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Protein Kinase Inhibitors - administration & dosage | Crizotinib - pharmacology | Gene Rearrangement | Piperidines - adverse effects | Anaplastic Lymphoma Kinase - biosynthesis | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Clinical Trials, Phase II as Topic | Lymphomas | Metabolites | Lung cancer, Non-small cell | Analysis | Statistical analysis | Cell survival | Small cell lung carcinoma | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Exposure | Regression analysis | Cancer therapies | Patients | Lymphoma | Confidence intervals | Statistical models | Safety | Hazard assessment | Protein-tyrosine kinase | Cancer | Tumors | Original
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 12/2018, Volume 58, Issue 12, pp. 1618 - 1628
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2017, Volume 79, Issue 3, pp. 559 - 568
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e20564 - e20564
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e20616 - e20616
Journal Article
Expert Opinion on Drug Safety, ISSN 1474-0338, 01/2013, Volume 12, Issue 1, pp. 65 - 79
Introduction: The peroxisome proliferator-activated receptor (PPAR)- Delta *a and - Delta *g agonists, fibrates and glitazones, are effective treatments for... 
Drugs | Side effects | Reviews | Urinary bladder | Diabetes mellitus | Insulin | Risk factors | Guidelines
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 07/2019, Volume 14, Issue 7, pp. 1233 - 1243
Introduction: At the prior data cutoff (February 9, 2017) the ALEX trial showed superior investigator-assessed progression-free survival (PFS) for alectinib... 
ALEX | EML4-ALK | Alectinib | Non–small cell lung cancer | NGS | ONCOLOGY | RESPIRATORY SYSTEM | Non-small cell lung cancer | CRIZOTINIB
Journal Article